Lymphoma & Leukemia Program
About Lymphoma and Leukemia
Since lymphoma is a cancer of the immune system, a major scientific goal of the Lymphoma and Leukemia Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
Program Aims:
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Program Directors
Program Directory
Lymphoma and Leukemia Clinical Trials
-
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Stanford is currently accepting patients for this trial. -
Feasibility Neurocognitive Outcome After Transplant
Stanford is currently accepting patients for this trial. -
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Stanford is currently accepting patients for this trial. -
Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia
Stanford is currently accepting patients for this trial.